208 related articles for article (PubMed ID: 33350072)
21. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
22. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
23. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract][Full Text] [Related]
24. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
25. The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China.
Zhang Y; Shen WX; Zhou LN; Tang M; Tan Y; Feng CX; Li P; Wang LQ; Chen MB
Biomed Res Int; 2020; 2020():9387167. PubMed ID: 32047821
[TBL] [Abstract][Full Text] [Related]
26. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
[TBL] [Abstract][Full Text] [Related]
27. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples.
Nemoto D; Yokose T; Katayama K; Murakami S; Kato T; Saito H; Suzuki M; Eriguchi D; Samejima J; Nagashima T; Ito H; Yamada K; Nakayama H; Masuda M
Thorac Cancer; 2021 Jan; 12(2):194-200. PubMed ID: 33185331
[TBL] [Abstract][Full Text] [Related]
28. External Validation of
Kim SW; DO SI; Na K
Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
30. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
31. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
32. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
Brisudova A; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
[TBL] [Abstract][Full Text] [Related]
33. Pathological criteria for multiplex gene-panel testing using next-generation sequencing in non-small cell lung cancer.
Mizote S; Matsumura M; Sekiya M; Sugiyama M; Sekine A; Kobayashi N; Kataoka T; Iwashita H; Okudela K
Cancer Treat Res Commun; 2022; 32():100614. PubMed ID: 35878517
[TBL] [Abstract][Full Text] [Related]
34. Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice.
Rao W; Guo L; Ling Y; Dong L; Li W; Ying J; Li W
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4889-4897. PubMed ID: 36305947
[TBL] [Abstract][Full Text] [Related]
35. Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing.
Ji X; Che N; Lin R; Chen J; Wu X
Pathol Res Pract; 2019 May; 215(5):1066-1070. PubMed ID: 30876750
[TBL] [Abstract][Full Text] [Related]
36. Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients.
O'Donnell P; May T; DeMartin K; Ferguson J; Halait H; Wei W; Yu K; Scudder S
Mol Diagn Ther; 2020 Aug; 24(4):451-460. PubMed ID: 32406048
[TBL] [Abstract][Full Text] [Related]
37. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
[TBL] [Abstract][Full Text] [Related]
38. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
39. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
